Latest Breaking News On - Positive phase - Page 1 : comparemela.com

Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)

- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to.

Los angelesUnited statesLasika seneviratneRaj malikSacituzumab govitecanEuropean society for medical oncologyCorporate communicationsAmerican society of clinical oncologyLos angeles cancer networkResearch triangle parkAmerican cancer societyExchange commissionTherapeutics incAssociation of outcomesPositive phaseMetastatic triple negative breast cancer

Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) - G1 Therapeutics (NASDAQ:GTHX)

- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data

United statesLos angelesRaj malikLasika seneviratneSacituzumab govitecanEuropean society for medical oncologyLos angeles cancer networkAmerican cancer societyResearch triangle parkCorporate communicationsExchange commissionTherapeutics incAmerican society of clinical oncologyAssociation of outcomesPositive phaseMetastatic triple negative breast cancer

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesCarl spanaBremelanotide coExchange commissionPrnewswire palatin technologies incCosette pharmaceuticalsSexual dysfunction programPalatin technologies incSymptom endpoints including the coMetabolic program obesitySecurities exchangePositive phasePrimary symptom endpointPain met statistical significanceMultiple symptom endpointsCo primary pain endpoint

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Angelos stergiouBruce mackleJoshua zeidnerLife sciences group incDrug administrationLeukemia researchCompany filed ip protectionWorld health organizationLifesci advisorsDivision of hematologyGenfleet therapeutics shanghai incMemorial sloan kettering cancer centerClinical cancer research commercial integrationPositive phaseResponse rateOptimal dose

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEric donnenfeldCarl spanaMichael raizmanSecurities exchangePrnewswire palatin technologies incAmerican society of cataractSymptom endpoints including the coPalatin technologies incPositive phaseResults includedPrimary symptom endpointPain met statistical significanceWeek treatment periodMultiple symptom endpointsCo primary pain endpoint